Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program.

Charles G PeterfyVibeke StrandAlan FriedmanStephen HallEduardo MyslerPatrick DurezXenofon BaraliakosJeffrey V EnejosaTim ShawYihan LiSu ChenIn-Ho Song

Published in: Rheumatology (Oxford, England) (2022)

ClinicalTrials.gov (https://clinicaltrials.gov), NCT02706873 and NCT02629159.

Keyphrases

rheumatoid arthritis
quality improvement
disease activity
oxidative stress
ankylosing spondylitis
interstitial lung disease
systemic lupus erythematosus
idiopathic pulmonary fibrosis